Protease inhibitor-sparing simplified maintenance therapy: a need for perspective

Area of Science:

• Internal Medicine
• Infectious Diseases
• Pharmacology

Background:

• Highly active antiretroviral therapy (HAART) has improved HIV management but is associated with metabolic abnormalities and body fat changes.
• Protease inhibitors (PIs) were initially implicated in these side effects, leading to trials comparing PI-based regimens with simplified maintenance therapy (SMT) without PIs.

Purpose of the Study:

• To evaluate the safety and efficacy of switching from PI-containing HAART to SMT in patients with well-controlled HIV.
• To assess the virological and metabolic outcomes associated with different SMT regimens.

Main Methods:

• Analysis of clinical trial data comparing continued PI use versus switching to SMT (abacavir, nevirapine, or efavirenz).
• Assessment of virological control, metabolic parameters (lipids, glucose), and treatment adherence.

Main Results:

• Evidence is insufficient to confirm the safety of switching from PIs to abacavir, nevirapine, or efavirenz.
• Patients with suboptimal pre-HAART treatment are at higher risk of virological failure when switched to SMT.
• Switching to abacavir-based SMT showed a reduction in total cholesterol; no additional benefits were observed for non-PI-based SMT.

Conclusions:

• Switching from PI-based HAART to SMT requires careful patient selection, especially for those with suboptimal prior treatment.
• Further research is needed to understand HAART-related metabolic toxicity and identify at-risk patients using pharmacogenetic tests.
• Newer drug formulations and PIs with reduced metabolic toxicity may alter the future role of SMT.